|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/07/22 Allscripts Healthcare Soluti… Inc 10-Q 9/30/22 105:20M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 5.36M
2: EX-10.1 Material Contract HTML 54K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 33K
11: R1 Document and Entity Information HTML 83K
12: R2 Consolidated Balance Sheets (Unaudited) HTML 166K
13: R3 Consolidated Balance Sheets (Unaudited) HTML 57K
(Parenthetical)
14: R4 Consolidated Statements of Operations (Unaudited) HTML 162K
15: R5 Consolidated Statements of Comprehensive Income HTML 67K
(Loss) (Unaudited)
16: R6 Consolidated Statements of Stockholders' Equity HTML 150K
(Unaudited)
17: R7 Consolidated Statements of Stockholders Equity HTML 32K
(Parenthetical)
18: R8 Consolidated Statements of Cash Flows (Unaudited) HTML 157K
19: R9 Basis of Presentation and Significant Accounting HTML 46K
Policies
20: R10 Revenue from Contracts with Customers HTML 247K
21: R11 Accounts Receivable HTML 55K
22: R12 Leases HTML 142K
23: R13 Business Combinations and Divestitures HTML 91K
24: R14 Fair Value Measurements and Long-term Investments HTML 196K
25: R15 Stockholders' Equity HTML 163K
26: R16 Earnings (Loss) Per Share HTML 244K
27: R17 Goodwill and Intangible Assets HTML 169K
28: R18 Debt HTML 220K
29: R19 Income Taxes HTML 78K
30: R20 Derivative Financial Instruments HTML 162K
31: R21 Accumulated Other Comprehensive Loss HTML 293K
32: R22 Contingencies HTML 42K
33: R23 Discontinued Operations HTML 381K
34: R24 Business Segments HTML 148K
35: R25 Supplemental Disclosures HTML 72K
36: R26 Basis of Presentation and Significant Accounting HTML 70K
Policies (Policies)
37: R27 Revenue from Contracts with Customers (Tables) HTML 231K
38: R28 Accounts Receivable (Tables) HTML 56K
39: R29 Leases (Tables) HTML 140K
40: R30 Business Combinations and Divestitures (Tables) HTML 78K
41: R31 Fair Value Measurements and Long-term Investments HTML 189K
(Tables)
42: R32 Stockholders' Equity (Tables) HTML 146K
43: R33 Earnings (Loss) Per Share (Tables) HTML 244K
44: R34 Goodwill and Intangible Assets (Tables) HTML 173K
45: R35 Debt (Tables) HTML 202K
46: R36 Income Taxes (Tables) HTML 64K
47: R37 Derivative Financial Instruments (Tables) HTML 159K
48: R38 Accumulated Other Comprehensive Loss (Tables) HTML 293K
49: R39 Discontinued Operations (Tables) HTML 380K
50: R40 Business Segments (Tables) HTML 138K
51: R41 Supplemental Disclosures (Tables) HTML 71K
52: R42 Basis of Presentation and Significant Accounting HTML 69K
Policies - Additional Information (Detail)
53: R43 Revenue from Contracts with Customers - Additional HTML 49K
Information (Detail)
54: R44 Revenue from Contracts with Customers - Summary of HTML 45K
Revenue Recognized on Various Performance
Obligations and Elected Accounting Expedients
(Detail)
55: R45 Revenue from Contracts with Customers - Summary of HTML 56K
Revenue by Type and Nature of Revenue Stream by
Reportable Segments (Detail)
56: R46 Revenue from Contracts with Customers - Summary of HTML 40K
Changes in Estimate of Credit Losses for Contract
Assets (Details)
57: R47 Accounts Receivable - Schedule of Changes in HTML 38K
Estimate of Credit Losses for Trade Accounts
Receivable (Detail)
58: R48 Leases - Additional Information (Detail) HTML 37K
59: R49 Leases - Summary of Operating Costs Associated HTML 37K
with Leased Assets (Detail)
60: R50 Leases - Supplemental Cash Flow Information for HTML 34K
Operating Leases (Detail)
61: R51 Leases - Summary of Balance Sheet Location and HTML 40K
Balances for Operating Leases (Detail)
62: R52 Leases - Summary of Future Maturities of Lease and HTML 51K
Non-Lease Components (Detail)
63: R53 Business Combinations and Divestitures - HTML 85K
Additional Information (Detail)
64: R54 Business Combinations and Divestitures - Schedule HTML 53K
of Assets Acquired and Liabilities Assumed
(Detail)
65: R55 Business Combinations and Divestitures - Schedule HTML 42K
of Acquired Intangible Assets Amortization
(Detail)
66: R56 Fair Value Measurements and Long-term Investments HTML 59K
- Summary of Financial Assets and Liabilities
Measured at Fair Value on Recurring Basis (Detail)
67: R57 Fair Value Measurements and Long-term Investments HTML 37K
- Summary of Changes in Liability Measured at Fair
Value on Recurring Basis (Detail)
68: R58 Fair Value Measurements and Long-term Investments HTML 48K
- Summary of Long-term Equity Investments Included
in Other Assets (Detail)
69: R59 Fair Value Measurements and Long-term Investments HTML 45K
- Additional Information (Detail)
70: R60 Stockholders' Equity - Additional Information HTML 70K
(Detail)
71: R61 Stockholders' Equity - Stock-Based Compensation HTML 44K
Expense (Detail)
72: R62 Stockholders' Equity - Stock-Based Awards Granted HTML 43K
(Detail)
73: R63 Earnings (Loss) Per Share - Calculations of HTML 98K
Earnings (Loss) Per Share (Detail)
74: R64 Earnings (Loss) Per Share - Anti-Dilutive Stock HTML 32K
Options, Restricted Stock Unit Awards and Warrants
Excluded from Computation of Diluted Earnings
(Loss) Per Share (Detail)
75: R65 Goodwill and Intangible Assets - Goodwill and HTML 51K
Intangible Assets (Detail)
76: R66 Goodwill and Intangible Assets - Changes in HTML 42K
Carrying Amount of Goodwill (Detail)
77: R67 Goodwill and Intangible Assets - Additional HTML 32K
Information (Detail)
78: R68 Debt - Debt Outstanding Excluding Lease HTML 43K
Obligations (Detail)
79: R69 Debt - Debt Outstanding Excluding Lease HTML 43K
Obligations (Parenthetical) (Detail)
80: R70 Debt - Interest Expense (Detail) HTML 42K
81: R71 Debt - Interest Expense Related to 0.875% HTML 41K
Convertible Senior Notes (Detail)
82: R72 Debt - Additional Information (Detail) HTML 101K
83: R73 Debt - Summary of Future Debt Payment Obligations HTML 54K
(Detail)
84: R74 Debt - Summary of Future Debt Payment Obligations HTML 34K
(Parenthetical) (Detail)
85: R75 Income Taxes - Effective Tax Rates (Detail) HTML 41K
86: R76 Income Taxes - Additional Information (Detail) HTML 43K
87: R77 Derivative Financial Instruments - Fair Value and HTML 43K
Balance Sheet Locations (Detail)
88: R78 Derivative Financial Instruments - Additional HTML 45K
Information (Detail)
89: R79 Derivative Financial Instruments - Derivatives HTML 45K
Instruments Designated as Cash Flow Hedges
(Detail)
90: R80 Accumulated Other Comprehensive Loss - Components HTML 66K
of Accumulated Other Comprehensive Loss (Detail)
91: R81 Accumulated Other Comprehensive Loss - Components HTML 33K
of Accumulated Other Comprehensive Loss
(Parenthetical) (Detail)
92: R82 Accumulated Other Comprehensive Loss - Income Tax HTML 79K
Effects Related to Components of Other
Comprehensive Income (Loss) (Detail)
93: R83 Contingencies - Additional Information (Detail) HTML 47K
94: R84 Discontinued Operations - Additional Information HTML 36K
(Detail)
95: R85 Discontinued Operations - Summary of Major Classes HTML 112K
of Assets and Liabilities as Reported on
Consolidated Balance Sheets (Detail)
96: R86 Discontinued Operations - Summary of Major Classes HTML 38K
of Assets and Liabilities as Reported on
Consolidated Balance Sheets (Parenthetical)
(Detail)
97: R87 Discontinued Operations - Summary of Major Income HTML 90K
and Expense Line Items Reported in Consolidated
Statements of Operations (Detail)
98: R88 Business Segments - Additional Information HTML 36K
(Detail)
99: R89 Business Segments - Revenues and Income (Loss) HTML 54K
from Operations Related to Segment Within
Reconciliation to Consolidated Amounts (Detail)
100: R90 Supplemental Disclosures - Supplemental HTML 47K
Disclosures (Detail)
103: XML IDEA XML File -- Filing Summary XML 203K
101: XML XBRL Instance -- mdrx-20220930_htm XML 5.72M
102: EXCEL IDEA Workbook of Financial Reports XLSX 192K
6: EX-101.CAL XBRL Calculations -- mdrx-20220930_cal XML 288K
9: EX-101.DEF XBRL Definitions -- mdrx-20220930_def XML 1.01M
7: EX-101.LAB XBRL Labels -- mdrx-20220930_lab XML 1.84M
8: EX-101.PRE XBRL Presentations -- mdrx-20220930_pre XML 1.45M
10: EX-101.SCH XBRL Schema -- mdrx-20220930 XSD 258K
104: JSON XBRL Instance as JSON Data -- MetaLinks 570± 938K
105: ZIP XBRL Zipped Folder -- 0000950170-22-022665-xbrl Zip 492K
| EX-32.1 |
Exhibit 32.1
The following statement is being made to the Securities and Exchange Commission solely for purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: Allscripts Healthcare Solutions, Inc.
Ladies and Gentlemen:
In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 USC 1350), each of the undersigned hereby certifies that:
(i) this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, which this statement accompanies, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(ii) the information contained in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, fairly presents, in all material respects, the financial condition and results of operations of Allscripts Healthcare Solutions, Inc.
Dated as of this 7th day of November, 2022.
|
|
|
/s/ Leah S. Jones |
|
Chief Executive Officer |
|
|
|
Chief Financial Officer |
A signed original of this written statement required by Section 906 has been provided to Allscripts Healthcare Solutions, Inc. and will be retained by Allscripts Healthcare Solutions, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/7/22 | None on these Dates | ||
| For Period end: | 9/30/22 | |||
| List all Filings | ||||